United European Gastroenterology Journal
Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver diseases. NAFLD spectrum begins from simple steatosis to non-alcoholic steatohepatitis (NASH), progressive fibrosis, cirrhosis, and even hepatocellular carcinoma. Although most NAFLD patients are overweight and obese, 30% are lean. We analyzed lean and non-lean NAFLD patients’ liver biopsies for cytokeratin 8/18 immunohistochemical staining differences.
Aims & Methods
Thirty biopsy-proven NAFLD patients (15 patients with BMI ≤ 25 kg/m2, 15 patients with BMI > 25 kg/m2) were included in the study. Demographic, biochemical, and histologic features of the patients were recorded. Biopsy specimens from our archive were re-stained with cytokeratin 8/18 marker and were re-evaluated by a single expert hepatopathologist according to Brunt’s classification, the NASH Clinical Research Network (NASH-CRN) scoring system, and fatty liver inhibition of progression (FLIP) algorithm.
The presence of pathological granular staining with cytokeratin 8/18 marker in hepatocytes positively correlated with ballooning degeneration (r=0.461, p=0.027), the grade of lobular inflammation according to the FLIP algorithm (r=0.461, p=0.027), the grade of lobular inflammation according to the NAFLD activity score (r=0.545, p=0.007), presence of portal inflammation (r=0.525, p=0.010), age (r=0.534, p=0.009), gender (r=0.464, p=0.026), serum glucose value (r=0.537, p=0.008), direct bilirubin (r=0.523, p=0.022) and HbA1c (r=0.758, p=0.029) levels, and negatively correlated with hemoglobin (r=-0.473, p=0.030) and hematocrit (r=-0.437, p=0.047) levels.
Telli P, Buyuk M, Ozturk NB, Istemihan Z, Nuriyev K, Atasoy A, et al. The diagnostic role of cytokeratin 8/18/ immunohistochemical marker for lean non-alcoholic fatty liver disease. United European Gastroenterol J. 2022 Oct;10(8 Suppl):899-900. doi:10.1002/ueg2.12295.